Novo Nordisk A/S (NYSE:NVO) Raised to Buy at Kepler Capital Markets

Novo Nordisk A/S (NYSE:NVO) was upgraded by Kepler Capital Markets from a “hold” rating to a “buy” rating in a report released on Thursday, MarketBeat reports.

Several other research analysts also recently issued reports on NVO. Morgan Stanley started coverage on Novo Nordisk A/S in a research note on Wednesday, February 12th. They set an “equal weight” rating for the company. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Finally, BMO Capital Markets dropped their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research report on Monday, December 23rd. Three equities research analysts have rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $145.25.

Novo Nordisk A/S Price Performance

Novo Nordisk A/S stock opened at $77.22 on Thursday. Novo Nordisk A/S has a one year low of $73.80 and a one year high of $148.15. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. The business has a fifty day moving average of $83.95 and a two-hundred day moving average of $103.24. The company has a market cap of $346.54 billion, a P/E ratio of 23.47, a price-to-earnings-growth ratio of 0.90 and a beta of 0.42.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. As a group, analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Institutional Trading of Novo Nordisk A/S

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Lighthouse Financial LLC purchased a new stake in Novo Nordisk A/S in the 4th quarter valued at about $1,811,000. Aegis Wealth Management LLC purchased a new stake in shares of Novo Nordisk A/S during the 4th quarter worth about $479,000. BridgePort Financial Solutions LLC purchased a new stake in shares of Novo Nordisk A/S during the 4th quarter worth about $540,000. Park Square Financial Group LLC purchased a new stake in shares of Novo Nordisk A/S during the 4th quarter worth about $29,000. Finally, Employees Retirement System of Texas grew its holdings in shares of Novo Nordisk A/S by 9.9% during the 4th quarter. Employees Retirement System of Texas now owns 72,964 shares of the company’s stock worth $6,276,000 after purchasing an additional 6,560 shares during the period. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.